Form of proxy for 2026 second extraordinary general meeting to be held on October 23, 2026
Filed with HKEX · Stock code 6872 · · 1 page · English
Summary by 6ix AI
This filing is a proxy form for the upcoming extraordinary general meeting of TenNor Therapeutics Suzhou Ltd.. It allows registered shareholders to appoint a proxy to vote on their behalf at the meeting scheduled for a specific date. The document includes instructions for completing the proxy form and details about the voting process.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
TenNor Therapeutics Suzhou Ltd. on 6ix
Earlier from TenNor Therapeutics Suzhou
- Notice of 2026 second extraordinary general meeting
- Circular of 2026 second extraordinary general meeting
- 2026 Interim report
- Formulation of the 2026 h share award scheme; and (2) amendments to the articles of association
- Poll results of the annual shareholders' meeting held on Monday, June 29, 2026
Later from TenNor Therapeutics Suzhou
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Voluntary announcement completion of enrollment of the first patient in the multi-center Phase IIb clinical trial of rifaquizinone (TNP-2092) administered via intra-articular injection for the treatment of prosthetic joint infection
- Poll results of the 2026 second extraordinary general meeting held on Friday, October 23, 2026 and amendments to the articles of association
- Articles of Association
- Voluntary announcement h share repurchase plan
Follow TenNor Therapeutics Suzhou into a list and get an email when it puts out news.
Follow TenNor Therapeutics Suzhou